Pharmacokinetics and metabolism of reboxetine

Reviews in Contemporary Pharmacotherapy

Volumn 11, Issue 5, 2000, Pages 283-293

  Fleishaker, Joseph C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; DEXTROMETHORPHAN; DIMETHYLNITROSAMINE DEMETHYLASE; FLUOXETINE; KETOCONAZOLE; LORAZEPAM; NORADRENALIN UPTAKE INHIBITOR; QUINIDINE; REBOXETINE;

AGE; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENANTIOMER; ENZYME ACTIVITY; FIRST PASS EFFECT; KIDNEY DISEASE; LIVER DYSFUNCTION; PHARMACOKINETICS; REVIEW; STEREOCHEMISTRY;

EID: 0033909461     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Avenoso A, Facciolà G, Scordo MG, Spina E. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers. Ther Drug Monit 1999; 21: 577-579.
2. Caccia S. Metabolism of the newer antidepressants: an overview of the pharmacological and pharmacokinetic implications. Drug Dispos 1998; 34: 281-302.
3. Cocchiara G, Battaglia R, Pevarello P, Strolin Benedetti M. Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur J Drug Metab Pharmacokinet 1991; 16: 231-239.
4. Connor TJ, Kelliher P, Harkin A, Kelly JP, Leonard BE. Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat. Eur J Pharmacol 1999; 379: 125-133.
5. Coulomb F, Ducret F, Fiorentini F et al. Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency. J Clin Pharmacol 2000; in press.
6. Davies DS, Murray S, Edwards RJ, Boobis AR. Inhibitory potential of reboxetine on major drug metabolizing forms of P450 in humans. American College of Neuropsychopharmacology 36th Annual Meeting. Waikoloa, Hawaii, December 8-12, 1997.
7. Denolle T, Pellizzoni C, Jannuzzo MG, Poggesi I. Hemodynamic effects of reboxetine in healthy male volunteers. Clin Pharmacol Ther 1999; 66: 282-287.
8. DeVane CL. Differential pharmacology of the newer antidepressants. J Clin Psychiatry 1998; 59 (Suppl 20): 85-93.
9. Dostert P, Benedetti MS, Pogessi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997; 7 (Suppl 1): S23-S35.
10. Edwards DM, Pellizzoni C, Breuel HP et al. Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 1995; 16: 443-460.
11. Fiorentini F, Poggesi I, Januzzo MG, Seiberling M, Dostert P, Strolin Benedetti M. Effect of lorazepam on the pharmacokinetics of reboxetine in healthy volunteers. Eur Neuropsychopharmacol 1995; 5: 300.
12. Fiorentini F, Poggesi I, Januzzo MG, Duchene P, Strolin Benedetti M. Pharmacokinetics of reboxetine, a new selective noradrenaline uptake inhibitor, in patients with various degrees of hepatic and renal insufficiency. Pharmacol Res 1997; 35: 239.
13. Fleishaker JC, Herman BD. Pearson LK, Ionita A, Mucci M. Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers. Clin Drug Invest 1999a; 18: 141-150.
14. Fleishaker JC, Mucci M, Pellizzoni C, Poggesi I. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. Biopharm Drug Dispos 1999b; 20: 53-57.
15. Fleishaker JC, Francom SF, Herman BD, Azie NE. Lack of effect of reboxetine on electrocardiographic parameters in healthy volunteers. Clin Pharmacol Ther 2000; 67: 109.
16. Gorman JM, Nemeroff CB. The role of norepinephrine in the treatment of depression. J Clin Psychiatry 1999; 60: 623-631.
17. Herman BD, Fleishaker JC, Brown MT. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. Clin Pharmacol Ther 1999; 66: 374-379.
18. Jannuzzo MG, Strolin Benedetti M, Duchene P, Dubini A, Dostert P. Pharmacokinetics of reboxetine in the elderly. Advances in simultaneous pharmacokinetic/pharmacodynamic modeling. Second International Symposium. Measurement and kinetics of in vivo drug effects. Book of abstracts 94-96. Noorwijkerhout, The Netherlands, 14-16 April, 1994.
19. Jannuzzo MG, Ryde M, Karlmark B et al. Pharmacokinetics of reboxetine in healthy volunteers of different ages. Eur Neuropsychopharmacol 1995a; 5: 300.
20. Jannuzzo MG, Bosc M, Renoux A, Dostert P, Strolin Benedetti M. Effect of reboxetine on the pharmacokinetics of lorazepam in healthy volunteers. Eur Neuropsychopharmacol 1995b; 5: 300-301.
21. Massana J, Möller H-J, Burrows GD, Montenegro RM. Reboxetine: a doubleblind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999; 14: 73-80.
22. Melloni P, Carniel G, della Torre A et al. Potential antidepressant agents, α-Aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur J Med Chem Chim Thér 1984; 19: 235-242.
23. Pellizzoni C, Strolin Benedelti M, Poggesi I, Frigerio E, Toon S, Langley SJ. Pharmacokinetics of reboxetine in healthy volunteers: relative bioavailability and food effect. Pharmacol Res 1995; 31 (Suppl): 41.
24. Pellizzoni C, Poggesi I, Jørgensen NP, Edwards DMF, Paus E, Strolin Benedetti M. Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. Biopharm Drug Dispos 1996; 17: 623-633.
25. Poggesi I, Pellizzoni C, Fleishaker JC. Pharmacokinetics of reboxetine in elderly patients with depressive disorders. Int J Clin Pharmacol Ther 2000; in press.
26. Rey E, Dostert P, d'Athis PH, Jannuzzo MG, Poggesi I, Olive G. Dose proportionality of reboxetine enantiomers in healthy volunteers. Biopharm Drug Dispos 1999; 20: 177-181.
27. Riva M, Brunello N, Rovescalli AC et al. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J Drug Dev 1989; 1: 243-253.
28. Rocchetti M, Pellizzoni C, Poggesi I et al. Genetic polymorphism and reboxetine metabolism. First Congress of the European Association for Clinical Pharmacology and Therapeutics. Thérapie 1995; Suppl: Abstract 80.
29. Strolin Benedelti M, Pellizzoni C, Poggesi I et al. Pharmacokinetics of reboxetine enantiomers in healthy volunteers. 12th International Congress of Pharmacology, Montreal, Canada, July 24-29, 1994.
30. Strolin Benedetti M, Frigerio E, Tocchetti P et al. Stereoselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality 1995; 7: 285-289.
31. Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999; 60: 400-406.
32. 450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos 1999: 27: 1334-1340.